PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för lifitegrast. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

14 hits

Bibliografisk träff 2016-07-22

Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials.

Holland EJ, Whitley WO, Sall K, Lane SS, Raychaudhuri A, Zhang SY, Shojaei A.

Curr Med Res Opin · journal article · DOI 10.1080/03007995.2016.1210107

Bibliografisk träff 2016-06-10

Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease.

Semba CP, Gadek TR.

Clin Ophthalmol · review-article; review; journal article · DOI 10.2147/opth.s110557

Bibliografisk träff 2016-06-01

Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.

Donnenfeld ED, Karpecki PM, Majmudar PA, Nichols KK, Raychaudhuri A, Roy M, Semba CP.

Cornea · clinical trial, phase iii; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1097/ico.0000000000000803

Bibliografisk träff 2016-01-22

Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease.

Perez VL, Pflugfelder SC, Zhang S, Shojaei A, Haque R.

Ocul Surf · review; journal article · DOI 10.1016/j.jtos.2016.01.001

Bibliografisk träff 2015-09-11

Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.

Tauber J, Karpecki P, Latkany R, Luchs J, Martel J, Sall K, Raychaudhuri A, Smith V, Semba CP, OPUS-2 Investigators.

Ophthalmology · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.ophtha.2015.08.001

Bibliografisk träff 2013-11-26

Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.

Sheppard JD, Torkildsen GL, Lonsdale JD, D'Ambrosio FA, McLaurin EB, Eiferman RA, Kennedy KS, Semba CP, OPUS-1 Study Group.

Ophthalmology · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.ophtha.2013.09.015

Bibliografisk träff 2012-12-20

Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eye.

Yandrapu S, Kompella UB.

J Ocul Pharmacol Ther · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1089/jop.2012.0210

Bibliografisk träff 2012-12-05

Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118).

Sun Y, Zhang R, Gadek TR, O'Neill CA, Pearlman E.

J Ocul Pharmacol Ther · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1089/jop.2012.0102

Bibliografisk träff 2012-04-27

Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study.

Paskowitz DM, Nguyen QD, Gehlbach P, Handa JT, Solomon S, Stark W, Shaikh O, Semba C, Gadek TR, Do DV.

Eye (Lond) · other; research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1038/eye.2012.68

Bibliografisk träff 2012-02-11

A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.

Semba CP, Torkildsen GL, Lonsdale JD, McLaurin EB, Geffin JA, Mundorf TK, Kennedy KS, Ousler GW.

Am J Ophthalmol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.ajo.2011.11.003

Bibliografisk träff 2012-01-31

Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.

Zhong M, Gadek TR, Bui M, Shen W, Burnier J, Barr KJ, Hanan EJ, Oslob JD, Yu CH, Zhu J, Arkin MR, Evanchik MJ, Flanagan WM, Hoch U, Hyde J, Prabhu S, Silverman JA, Wright J.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/ml2002482

Bibliografisk träff 2011-05-16

The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs.

Murphy CJ, Bentley E, Miller PE, McIntyre K, Leatherberry G, Dubielzig R, Giuliano E, Moore CP, Phillips TE, Smith PB, Prescott E, Miller JM, Thomas P, Scagliotti R, Esson D, Gadek T, O'Neill CA.

Invest Ophthalmol Vis Sci · research support, non-u.s. gov't; journal article · DOI 10.1167/iovs.09-5078

Bibliografisk träff 2010-05-05

Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR).

Rao VR, Prescott E, Shelke NB, Trivedi R, Thomas P, Struble C, Gadek T, O'Neill CA, Kompella UB.

Invest Ophthalmol Vis Sci · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1167/iovs.09-5144

Bibliografisk träff 2010-03-24

Safety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 antagonist ophthalmic solution (SAR 1118) in healthy adults.

Semba CP, Swearingen D, Smith VL, Newman MS, O'Neill CA, Burnier JP, Haughey DB, Gadek TR.

J Ocul Pharmacol Ther · randomized controlled trial; journal article · DOI 10.1089/jop.2009.0105